Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants | --- | |------------------------------------------------| | | | Louise Wilkie - Investor Relations | | Sandy Macrae - Chief Executive Officer | | Rob Schott - Head of Development | | Jason Fontenot - Chief Scientific Officer | | Prathyusha Duraibabu - Chief Financial Officer | | Bettina Cockroft - Chief Medical Officer | | Conference Call Participants | | Yanan Zhu - Wells Fargo | | Nicole ...

Sangam Pioneering the Future of Genomic Medicines February 2022 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi, ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Â | --- | |--------------------------------------------------| | | | Company Participants | | Aron Feingold - Head of Corporate Communications | | Sandy Macrae - CEO | | Mark McClung - COO | | Prathyusha Duraibabu - CFO | | Jason Fontenot - Chief Scientific Officer | | Rob Schott - Head of Development | | Bettina Cockroft - Chief Medical Officer | | Conference Call Participants | | Nicole Germino - Truist ...

Sangam Pioneering the Future of Genomic Medicines February 2022 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi, ...

Sangam Pioneering the Future of Genomic Medicines January 2022 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi, C ...

Sang Corporate Presentation November 2021 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi, CAR-Treg and other technologies ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2021 Earnings Conference Call November 4, 2021 9:15 AM ET Company Participants Aron Feingold – Head-Corporate Communications Sandy Macrae – Chief Executive Officer Prathyusha Duraibabu – Chief Financial Officer Bettina Cockroft – Chief Medical Officer Rob Schott – Head-Development Mark McClung – Chief Operating Officer Conference Call Participants Aspen Mori – Bank of America Yanan Zhu – Wells Fargo Luca Issi – RBC Capital Maury Raycroft – Jefferies Nicole Germino ...

Sangam Corporate Presentation August 2021 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi, CAR-Treg and other technologies ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2022 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Aron Feingold - Head of Corporate Communications & Investor Relations Officer Sandy Macrae - President & Chief Executive Officer Prathyusha Duraibabu - Chief Financial Officer Rob Schott - Senior Vice President & Head of Development Jason Fontenot - Senior Vice President & Chief Scientific Officer Mark McClung - Executive Vice President & Chief Business Officer Conference Call Participant ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2021 Earnings Conference Call May 4, 2021 5:00 PM ET Company Participants Aron Feingold - Head of Corporate Communications and Investor Relations Officer Sandy Macrae - President and Chief Executive Officer Robert Schott - Senior Vice President and Head of Development Jason Fontenot - Senior Vice President and Chief Scientific Officer Mark McClung - Executive Vice President and Chief Business Officer Bettina Cockroft - Senior Vice President and Chief Medical Offic ...